Breaking down trending topics, clinical studies, and articles related to alternative mental health therapies including plant based medicine, psychedelic therapy, and functional medicine with the insights of our highly trained clinical pharmacists. Building a community and inspiring hope for those looking to live better!
neuralpharm.substack.com (https://neuralpharm.substack.com?utm_medium=podcast)
References:
Psychedelics legislation in Colorado Springs: https://gazette.com/health/fountain-joins-colorado-springs-in-seeking-to-regulate-fledgling-psychedelic-mushroom-industry/article_22a66456-a1da-11ef-a515-57588c741084.html
Oregon Psilocybin Ballot Measure Results: https://www.opb.org/article/2024/11/07/psilocybin-ban-mushroom-hallucinogenic-ballot-politics-elections-oregon/
Vermont Psychedelic Working Group Final Report: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://legislature.vermont.gov/assets/Legislative-Reports/The-Psychedelic-Therapy-Advisory-Working-Group_Final-Report.pdf
US Life Expectancy Expected to Decline to 66th Globally by 2050: https://www.healthdata.org/news-events/newsroom/news-releases/increases-us-life-expectancy-forecasted-stall-2050-poorer-health#:~:text=Life%20expectancy%20in%20the%20US,2022%20to%2066th%20in%202050
United Healthcare uses faulty AI to deny claims: https://www.cbsnews.com/news/unitedhealth-lawsuit-ai-deny-claims-medicare-advantage-health-insurance-denials/
DEA Funding chart: https://crsreports.congress.gov/product/pdf/R/R44576
See here also, Why is the FDA funded by the companies it regulates?: https://today.uconn.edu/2021/05/why-is-the-fda-funded-in-part-by-the-companies-it-regulates-2/
Other references to topics discussed on this edition of podcast:
See Colby’s previous article on Measure 110 in Oregon—which decriminalized nearly all categories of drugs, and has since been overturned:
Right to Try bill articles (since this was discussed on this edition of podcast):
Trump gave patients “Right to Try” but it hasn’t helped them: https://www.statnews.com/2024/08/02/trump-gave-patients-right-to-try-it-hasnt-helped-them/
DEA says Right to Try doesn’t include substances listed as Schedule I: https://www.marijuanamoment.net/in-case-on-psilocybin-access-for-cancer-patients-dea-says-federal-right-to-try-law-does-not-provide-any-exemptions-from-controlled-substance-act/
Understanding the Right to Try act: https://pmc.ncbi.nlm.nih.gov/articles/PMC7416898/
Get full access to Neural Pharm at neuralpharm.substack.com/subscribe (https://neuralpharm.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4)
20 Nov 2024
Kanna Alkaloids: Nature's MDMA?
Industry expert Dr. Bennett and his team discuss the potential of kanna alkaloids as a natural alternative to MDMA, offering a promising avenue for delayed chronic disease progression and improved mental health outcomes.
9 Aug 2024
Breaking down the FDA Advisory Panel Decision on MDMA
**Note this was recorded the first week of July before President Biden announced he would not run for re-election. I know that feels like a lifetime ago but just jump in your time machine for a bit at the beginning of the podcast please. We will likely start our next episode on the pharmacology of Kanna with a “catch up” on Kamala Harris v Trump**
Footnotes, References and corrections:
See below to watch the live stream of the FDA advisory panel decision on MDMA Assisted Therapy; a review of the MAPP1 and MAPP2 trial data:
To review the MAPP1 and MAPP2 trials, listen to our first episode here (https://substack.com/@neuralpharm/p-126522144)
To read about how the FDA is funded, and what “user fees” are here (https://www.fda.gov/industry/fda-user-fee-programs/fda-user-fees-explained#:~:text=To%20support%20its%20public%20health,paid%20by%20certain%20other%20entities.)
To read the open letter from the Heroic Hearts Project (referenced by Chris) on the FDA advisory panel’s decision on veterans mental health, click on this link (https://heroicheartsproject.org/exposing-icers-anti-veteran-campaign-against-mdma-assisted-therapy/):
To read a bipartisan letter to President Biden in support of MDMA assisted therapy, click here (https://www.ajmc.com/view/bipartisan-letter-to-president-biden-highlights-promise-of-mdma-therapy-for-ptsd)
To listen to an interview in Psychedelics Today referenced by Colby in the podcast with Dr. Amanda Holley, a regulatory consultant and pharmacologist in non-clinical drug development, click here (https://podcasts.apple.com/us/podcast/pt522-an-inside-look-at-the-fda-and-early/id1114398275?i=1000659426670).
To read about GLP1 compounding regulations, and how big pharma is lying about owning exclusivity to semaglutide and tirzepatide, click here (http://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-11-March-2024.pdf) for a statement from the Alliance for Pharmacy Compounding.
FACT CHECKS
—Colby erroneously said the FDA advisory panel reviewed only phase 2 trial data from Lykos; in reality it was phase 3 data from the MAPP1 and MAPP2 trials
—ICER (https://icer.org/who-we-are/independent-funding/sources-of-funding/), which is referenced several times in the episode stands for the Institute for Clinical and Economic Review, an organization that discusses the pharmacoeconomic utility of pharmaceutical therapies. Chris claimed they were mostly funded by user fees from manufacturers, similar to the FDA, but ICER claims they receive most funding from non-profit sources, with only 14% from manufacturers. To read more about ICER’s letter in regards to MDMA assisted therapy, review my previous article on the topic here (https://substack.com/@neuralpharm/p-143252241). (Note the Heroic Hearts project uncovered ICER’s potential conflicts of interest not known to me at the time of this publication).
—Not necessarily a fact check, as at the time we recorded our information was correct, but as news moves quickly it has been revealed through toxicology testing that some Diamond Shruumz products do contain psilocybin (https://www.statnews.com/2024/07/18/legal-psychedelic-mushrooms-actually-contain-illegal-hallucinogens-study-shows/) despite the manufacturers claims they don’t. The FDA possibly didn’t know this either at the time of their original publication. To our listeners, please do not consume any products from this brand, as they have already been associated with 113 illnesses and 2 deaths nationwide (https://www.cbsnews.com/news/recalled-diamond-shruumz-edibles/).
Get full access to Neural Pharm at neuralpharm.substack.com/subscribe (https://neuralpharm.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Podcast Authority Score: 40 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
70
Social presence
0
YouTube
0
Engagement
27
Contact Neural Pharm Podcast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Neural Pharm Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
